TABLE 2.

Serial CSF findings in TBM patients from the LZD-BR and BR groups^a

Finding	LZD-BR group data (median [IQR]c)	BR group data (median [IQR])	P valueb
CSF/blood glucose ratio
Baseline	0.26 (0.17–0.36)	0.28 (0.19–0.33)	0.79
After 2-wk treatment	0.29 (0.26–0.33)	0.33 (0.25–0.40)	0.35
After 4-wk treatment	0.40 (0.35–0.47)	0.34 (0.27–0.36)	0.04
CSF white blood cell count (×106/liter)
Baseline	110 (50–255)	130 (52–250)	0.97
After 2-wk treatment	42 (9–80)	86 (25–120)	0.14
After 4-wk treatment	17 (8–40)	42 (23–105)	0.02
CSF protein concentration (g/liter)
Baseline	2.23 (1.56–3.87)	1.55 (1.37–2.16)	0.10
After 2-wk treatment	1.44 (1.21–2.13)	1.33 (0.95–1.75)	0.55
After 4-wk treatment	1.07 (0.64–1.81)	1.41 (0.73–1.62)	0.52

^aLZD, linezolid; BR, background regimen; TBM, tuberculous meningitis.

^bA P value of <0.05 was considered statistically significant.

^cIQR, interquartile range.